)
Techno Medica (6678) investor relations material
Techno Medica Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Net sales for the quarter ended June 30, 2026, rose 25.3% year-over-year to ¥2,202 million.
Operating profit reached ¥236 million, a significant turnaround from a ¥2 million loss in the prior year.
Ordinary profit surged to ¥243 million from ¥23 million year-over-year.
Net profit increased sharply to ¥158 million, up from ¥16 million in the same quarter last year.
Basic earnings per share rose to ¥23.86 from ¥2.38 year-over-year.
Financial highlights
Gross profit improved to ¥1,049 million from ¥811 million year-over-year.
Selling, general and administrative expenses remained stable at ¥812 million.
Total assets decreased to ¥16,239 million as of June 30, 2026, from ¥17,966 million at March 31, 2026.
Net assets declined to ¥13,709 million from ¥14,410 million at the previous fiscal year-end.
Equity-to-asset ratio improved to 84.4% from 80.2% year-over-year.
Outlook and guidance
Annual dividend forecast for the fiscal year ending March 31, 2027, is ¥93 per share, down from ¥129 per share in the previous year.
No revisions to the dividend forecast were announced.
Management cautions that actual results may differ due to economic and market factors.
- Q1 profits and revenue surged on robust sales, with full-year guidance maintained.6678
Q1 202521 Jul 2026 - Revenue up, profits down; overseas sales strong, cost pressures persist, outlook unchanged.6678
Q2 202521 Jul 2026 - Revenue steady, but profits fell sharply on higher costs; outlook unchanged.6678
Q3 202521 Jul 2026 - Revenue fell 3.7% as domestic delays offset strong overseas growth; profits declined year-over-year.6678
Q4 202521 Jul 2026 - Q1 FY2026 revenue fell 12.1% and net income dropped 90.5% year-over-year.6678
Q1 202621 Jul 2026 - Slight revenue and profit declines, but guidance and dividend unchanged; strong equity ratio.6678
Q2 202621 Jul 2026 - Revenue and profit surged on robust blood collection system sales; outlook remains strong.6678
Q3 202621 Jul 2026 - Revenue and profit rose on robust blood collection system sales, but FY2027 outlook is cautious.6678
Q4 202621 Jul 2026
Next Techno Medica earnings date
Next Techno Medica earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)